Sulforaphane impaired immune checkpoint blockade therapy through activating ΔNP63α/PD‐L1 axis in gastric cancer

Qi Zhang,Chenying Yang,Zhijian Ma,Liangwen Ye,Yunfeng Wu,Caiyun Zhong,Ye Shi,Mingming Zhu
DOI: https://doi.org/10.1002/mc.23749
2024-05-25
Molecular Carcinogenesis
Abstract:Sulforaphane (SFN) exerts anticancer effect on various cancers including gastric cancer. However, the regulatory effect of SFN on programmed death‐ligand 1 (PD‐L1) and checkpoint blockade therapy in gastric cancer have not been elucidated. Here we demonstrated that SFN suppressed gastric cancer cell growth both in vitro and in vivo study. SFN upregulated PD‐L1 expression through activating ΔNP63α in gastric cancer cells. Further, we found that SFN impaired the anticancer effect of anti‐PD‐L1 monoclonal antibody (α‐PD‐L1 mab) on gastric cancer cells. These results uncover a novel PD‐L1 regulatory mechanism and the double‐edged role of SFN in gastric cancer intervention.
oncology,biochemistry & molecular biology
What problem does this paper attempt to address?